1. Home
  2. MGF vs MGNX Comparison

MGF vs MGNX Comparison

Compare MGF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGF
  • MGNX
  • Stock Information
  • Founded
  • MGF 1987
  • MGNX 2000
  • Country
  • MGF United States
  • MGNX United States
  • Employees
  • MGF N/A
  • MGNX N/A
  • Industry
  • MGF Trusts Except Educational Religious and Charitable
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGF Finance
  • MGNX Health Care
  • Exchange
  • MGF Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • MGF 100.1M
  • MGNX 87.7M
  • IPO Year
  • MGF N/A
  • MGNX 2013
  • Fundamental
  • Price
  • MGF $3.12
  • MGNX $1.24
  • Analyst Decision
  • MGF
  • MGNX Hold
  • Analyst Count
  • MGF 0
  • MGNX 9
  • Target Price
  • MGF N/A
  • MGNX $5.33
  • AVG Volume (30 Days)
  • MGF 104.4K
  • MGNX 2.6M
  • Earning Date
  • MGF 01-01-0001
  • MGNX 08-05-2025
  • Dividend Yield
  • MGF 7.64%
  • MGNX N/A
  • EPS Growth
  • MGF N/A
  • MGNX N/A
  • EPS
  • MGF N/A
  • MGNX N/A
  • Revenue
  • MGF N/A
  • MGNX $154,050,000.00
  • Revenue This Year
  • MGF N/A
  • MGNX N/A
  • Revenue Next Year
  • MGF N/A
  • MGNX N/A
  • P/E Ratio
  • MGF N/A
  • MGNX N/A
  • Revenue Growth
  • MGF N/A
  • MGNX 255.31
  • 52 Week Low
  • MGF $2.91
  • MGNX $0.99
  • 52 Week High
  • MGF $3.46
  • MGNX $5.77
  • Technical
  • Relative Strength Index (RSI)
  • MGF 63.28
  • MGNX 38.61
  • Support Level
  • MGF $3.06
  • MGNX $1.26
  • Resistance Level
  • MGF $3.09
  • MGNX $1.41
  • Average True Range (ATR)
  • MGF 0.03
  • MGNX 0.17
  • MACD
  • MGF 0.00
  • MGNX -0.03
  • Stochastic Oscillator
  • MGF 94.74
  • MGNX 1.10

About MGF MFS Government Markets Income Trust

MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: